NuMedii
The AI engine Fit Assessment
BetaNuMedii effectively leverages machine learning and AI to discover new patterns, expand therapeutic options, and identify potential drug repurposing opportunities.
Blurb
NuMedii is a biotechnology company that discovers and de-risks effective drugs by translating life sciences big data into therapies.
HQ Location
United States
Founded
2008
Employees
1 - 10
Total funding raised
$5.50M
Last Funding Event
Series A, $2.00M, August 17, 2015
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Repurposing
Operator of a biotechnology company intended to address unmet medical needs. The company identifies compounds that modulate diverse networks involved in diseases and can help with myriad aspects of drug discovery including identifying patient subgroups, new therapeutic options and biomarkers, enabling researchers to harness big data and artificial intelligence to rapidly discover connections between drugs and diseases at a systems level.